By Fineline Cube 
US-based AbbVie (NYSE: ABBV) this week announced a licensing agreement with IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation, Inc. (IGI). The deal centers on ISB 2001, IGI’s first-in-class trispecific T-cell engager (TCE) developed using its proprietary BEAT protein platform.
Innovative Trispecific T-cell Engager
ISB 2001 targets BCMA and CD38 on myeloma cells and CD3 on T cells. It is currently in Phase I clinical study for relapsed/refractory multiple myeloma (R/R MM), an indication awarded Orphan Drug Designation by the US FDA in July 2023 and Fast Track Designation in May 2025. This innovative TCE represents a promising approach to treating complex diseases.
Terms of the Agreement
Under the agreement, AbbVie gains exclusive rights to develop, manufacture, and commercialize ISB 2001 in North America, Europe, Japan, and Greater China. IGI will receive USD 700 million upfront payment upon regulatory approval and is eligible for up to USD 1.225 billion in additional development, regulatory, and sales-based milestone payments. IGI will also receive tiered, double-digit royalties on net sales.-Fineline Info & Tech